CME/CE

Use the tool below to view all available Prova Series

Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
CME/CE
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
0.25 credits
- Naim Alkhouri, MD, FAASLD, DABOM
0.25 credits
Pruritus In PN and AD: Challenge How You Manage Itch
Pruritus In PN and AD: Challenge How You Manage Itch
CME/CE
Pruritus In PN and AD: Challenge How You Manage Itch
1.00 credit
- Peter A. Lio, MD
1.00 credit
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 6 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 6 episodes
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
MinuteCE®
Next-Generation Innovations: The Future of CELMoDs in Myeloma
1.00 program credit
- Noopur Raje, MD
1.00 program credit
 Real-World Ready: Practical Tips for Community Oncologists
 Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®
 Real-World Ready: Practical Tips for Community Oncologists
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit

CME/CE

Popular

Title

Share on ReachMD